Systemic Lupus Erythematosus - Pipeline Review, H2 2017

  • ID: 4426924
  • Drug Pipelines
  • 427 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Boehringer Ingelheim GmbH
  • Genentech Inc
  • Immupharma Plc
  • MedImmune LLC
  • Principia Biopharma Inc
  • MORE
Systemic Lupus Erythematosus - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H2 2017, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.

Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 28, 25, 40, 4 and 3 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 9 and 1 molecules, respectively.

Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Boehringer Ingelheim GmbH
  • Genentech Inc
  • Immupharma Plc
  • MedImmune LLC
  • Principia Biopharma Inc
  • MORE
Introduction

Systemic Lupus Erythematosus - Overview

Systemic Lupus Erythematosus - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Systemic Lupus Erythematosus - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development

AbbVie Inc

Ablynx NV

ACEA Biosciences Inc

AiCuris GmbH & Co KG

Amgen Inc

Asahi Kasei Pharma Corp

Atlantic Bio Sci LLC

Aurinia Pharmaceuticals Inc

Bio-Path Holdings Inc

Biogen Inc

Biotest AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Celgene Corp

Corestem Inc

CuraVac Inc

Deltanoid Pharmaceuticals Inc

Domainex Ltd

Eisai Co Ltd

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

Galapagos NV

Genentech Inc

Genosco Inc

Genovax Srl

Gilead Sciences Inc

GlaxoSmithKline Plc

HanAll Biopharma Co Ltd

Hanmi Pharmaceuticals Co Ltd

Idorsia Ltd

Immungenetics AG

Immunomedics Inc

Immunwork Inc

Immupharma Plc

Invion Ltd

Janus Biotherapeutics Inc

Johnson & Johnson

K-Stemcell Co Ltd

Karyopharm Therapeutics Inc

KPI Therapeutics Inc

Kyowa Hakko Kirin Co Ltd

Lead Discovery Center GmbH

LSK BioPartners Inc

MacroGenics Inc

MedAnnex Ltd

Medestea Research & Production SpA

MedImmune LLC

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Mitsubishi Tanabe Pharma Corp

Mount Tam Biotechnologies Inc

Nektar Therapeutics

Neovacs SA

Nippon Chemiphar Co Ltd

Novartis AG

Nuevolution AB

Omeros Corp

Pfizer Inc

Principia Biopharma Inc

Ra Pharmaceuticals Inc

RedHill Biopharma Ltd

Sarepta Therapeutics Inc

SBI Biotech Co Ltd

Takeda Pharmaceutical Co Ltd

TheraMAB LLC

TxCell SA

UCB SA

Xencor Inc

XTL Biopharmaceuticals Ltd

Zai Lab Ltd

Systemic Lupus Erythematosus - Drug Profiles

(clarithromycin + clofazimine + rifabutin) - Drug Profile

abatacept - Drug Profile

ABS-11 - Drug Profile

AC-058 - Drug Profile

ACY-1083 - Drug Profile

ACY-738 - Drug Profile

aldesleukin - Drug Profile

aldesleukin - Drug Profile

AMG-557 - Drug Profile

AMG-570 - Drug Profile

amiselimod hydrochloride - Drug Profile

anifrolumab - Drug Profile

Annexuzlimab - Drug Profile

Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile

APT-602 - Drug Profile

AT-791 - Drug Profile

atacicept - Drug Profile

baricitinib - Drug Profile

bee venom [Apis mellifera] allergen extract - Drug Profile

belimumab - Drug Profile

belimumab + rituximab - Drug Profile

BI-655064 - Drug Profile

BI-705564 - Drug Profile

BIIB-059 - Drug Profile

BIIB-068 - Drug Profile

Bispecific Monoclonal Antibody to Inhibit CD22 and CD20 for Autoimmune Disorders and Oncology - Drug Profile

BL-5923 - Drug Profile

BMS-986165 - Drug Profile

bortezomib - Drug Profile

BT-063 - Drug Profile

C-15231A - Drug Profile

CC-90008 - Drug Profile

Cellular Immunotherapy for Autoimmune Diseases and Transplantation - Drug Profile

Cellular Immunotherapy for Epstein-Barr Viral Infections, Multiple Sclerosis and Systemic Lupus Erythematosus - Drug Profile

Cellular Immunotherapy to Target CD19 for Oncology and Immunology - Drug Profile

cenerimod - Drug Profile

CS-20AT04 - Drug Profile

dalazatide - Drug Profile

dapirolizumab pegol - Drug Profile

DMXD-011 - Drug Profile

DP-001 - Drug Profile

Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis - Drug Profile

Drugs to Inhibit BAFF and APRIL for Systemic Lupus Erythematosus - Drug Profile

E-6446 - Drug Profile

edratide - Drug Profile

ENTX-LN - Drug Profile

evobrutinib - Drug Profile

faralimomab - Drug Profile

filgotinib - Drug Profile

forigerimod acetate - Drug Profile

GDC-0853 - Drug Profile

GNKS-356 - Drug Profile

GS-9876 - Drug Profile

GX-101 - Drug Profile

HCI-1401 - Drug Profile

HE-33 - Drug Profile

HL-161 - Drug Profile

iberdomide hydrochloride - Drug Profile

ICP-022 - Drug Profile

IL-233 - Drug Profile

IMP-10 - Drug Profile

INV-103 - Drug Profile

INV-17 - Drug Profile

INV-88 - Drug Profile

ixazomib citrate - Drug Profile

JB-6121 - Drug Profile

JNJ-0839 - Drug Profile

JNJ-56022473 - Drug Profile

KPT-350 - Drug Profile

lenabasum - Drug Profile

lulizumab pegol - Drug Profile

MEDI-7734 - Drug Profile

MGD-010 - Drug Profile

milatuzumab - Drug Profile

mizoribine - Drug Profile

NC-2400 - Drug Profile

NCS-613 - Drug Profile

NKTR-358 - Drug Profile

NUE-7770 - Drug Profile

obinutuzumab - Drug Profile

OMS-721 - Drug Profile

P-Dex - Drug Profile

PF-06823859 - Drug Profile

poseltinib - Drug Profile

prexigebersen - Drug Profile

PRN-1008 - Drug Profile

RA-101495 - Drug Profile

RCT-18 - Drug Profile

RSLV-132 - Drug Profile

RSLV-133 - Drug Profile

SBI-9674 - Drug Profile

SKIO-703 - Drug Profile

SM-03 - Drug Profile

SM-934 - Drug Profile

Small Molecule to Agonize CD11b for Systemic Lupus Erythematosus - Drug Profile

Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology - Drug Profile

Small Molecules for Dermatology, Immunology, Metabolic and CNS Disorders - Drug Profile

Small Molecules for Respiratory and Immunology - Drug Profile

Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile

Small molecules to Inhibit PAD for Autoimmune Diseases, Multiple Sclerosis and Oncology - Drug Profile

Stem Cell Therapy for Musculoskeletal, CNS Disorders, Dermatology, Immunology, Oncology and Cardiovascular Disease - Drug Profile

Synthetic Peptide to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile

Synthetic Peptides for Systemic Lupus Erythematosus - Drug Profile

TAB-08 - Drug Profile

TAK-079 - Drug Profile

TAM-01 - Drug Profile

TE-2324 - Drug Profile

tofacitinib citrate - Drug Profile

ustekinumab - Drug Profile

Vaccine for Systemic Lupus Erythematosus - Drug Profile

Vaccine to Target IFN-Alpha for Metabolic Disorders, Immunology, Infectious Diseases and Musculoskeletal Disorders - Drug Profile

venetoclax - Drug Profile

VISTA-Ig - Drug Profile

vobarilizumab - Drug Profile

voclosporin - Drug Profile

WITH-1101 - Drug Profile

XL-499 - Drug Profile

XmAb-5871 - Drug Profile

ZL-1101 - Drug Profile

Systemic Lupus Erythematosus - Dormant Projects

Systemic Lupus Erythematosus - Discontinued Products

Systemic Lupus Erythematosus - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Systemic Lupus Erythematosus, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Systemic Lupus Erythematosus - Pipeline by AbbVie Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by Ablynx NV, H2 2017

Systemic Lupus Erythematosus - Pipeline by ACEA Biosciences Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by AiCuris GmbH & Co KG, H2 2017

Systemic Lupus Erythematosus - Pipeline by Amgen Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by Asahi Kasei Pharma Corp, H2 2017

Systemic Lupus Erythematosus - Pipeline by Atlantic Bio Sci LLC, H2 2017

Systemic Lupus Erythematosus - Pipeline by Aurinia Pharmaceuticals Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by Bio-Path Holdings Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by Biogen Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by Biotest AG, H2 2017

Systemic Lupus Erythematosus - Pipeline by Boehringer Ingelheim GmbH, H2 2017

Systemic Lupus Erythematosus - Pipeline by Bristol-Myers Squibb Co, H2 2017

Systemic Lupus Erythematosus - Pipeline by Celgene Corp, H2 2017

Systemic Lupus Erythematosus - Pipeline by Corestem Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by CuraVac Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by Deltanoid Pharmaceuticals Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by Domainex Ltd, H2 2017

Systemic Lupus Erythematosus - Pipeline by Eisai Co Ltd, H2 2017

Systemic Lupus Erythematosus - Pipeline by Eli Lilly and Co, H2 2017

Systemic Lupus Erythematosus - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Systemic Lupus Erythematosus - Pipeline by Galapagos NV, H2 2017

Systemic Lupus Erythematosus - Pipeline by Genentech Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by Genosco Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by Genovax Srl, H2 2017

Systemic Lupus Erythematosus - Pipeline by Gilead Sciences Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by GlaxoSmithKline Plc, H2 2017

Systemic Lupus Erythematosus - Pipeline by HanAll Biopharma Co Ltd, H2 2017

Systemic Lupus Erythematosus - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017

Systemic Lupus Erythematosus - Pipeline by Idorsia Ltd, H2 2017

Systemic Lupus Erythematosus - Pipeline by Immungenetics AG, H2 2017

Systemic Lupus Erythematosus - Pipeline by Immunomedics Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by Immunwork Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by Immupharma Plc, H2 2017

Systemic Lupus Erythematosus - Pipeline by Invion Ltd, H2 2017

Systemic Lupus Erythematosus - Pipeline by Janus Biotherapeutics Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by Johnson & Johnson, H2 2017

Systemic Lupus Erythematosus - Pipeline by K-Stemcell Co Ltd, H2 2017

Systemic Lupus Erythematosus - Pipeline by Karyopharm Therapeutics Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by KPI Therapeutics Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017

Systemic Lupus Erythematosus - Pipeline by Lead Discovery Center GmbH, H2 2017

Systemic Lupus Erythematosus - Pipeline by LSK BioPartners Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by MacroGenics Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by MedAnnex Ltd, H2 2017

Systemic Lupus Erythematosus - Pipeline by Medestea Research & Production SpA, H2 2017

Systemic Lupus Erythematosus - Pipeline by MedImmune LLC, H2 2017

Systemic Lupus Erythematosus - Pipeline by Merck & Co Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by Merck KGaA, H2 2017

Systemic Lupus Erythematosus - Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017

Systemic Lupus Erythematosus - Pipeline by Mount Tam Biotechnologies Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by Nektar Therapeutics, H2 2017

Systemic Lupus Erythematosus - Pipeline by Neovacs SA, H2 2017

Systemic Lupus Erythematosus - Pipeline by Nippon Chemiphar Co Ltd, H2 2017

Systemic Lupus Erythematosus - Pipeline by Novartis AG, H2 2017

Systemic Lupus Erythematosus - Pipeline by Nuevolution AB, H2 2017

Systemic Lupus Erythematosus - Pipeline by Omeros Corp, H2 2017

Systemic Lupus Erythematosus - Pipeline by Pfizer Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by Principia Biopharma Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by Ra Pharmaceuticals Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by RedHill Biopharma Ltd, H2 2017

Systemic Lupus Erythematosus - Pipeline by Sarepta Therapeutics Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by SBI Biotech Co Ltd, H2 2017

Systemic Lupus Erythematosus - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017

Systemic Lupus Erythematosus - Pipeline by TheraMAB LLC, H2 2017

Systemic Lupus Erythematosus - Pipeline by TxCell SA, H2 2017

Systemic Lupus Erythematosus - Pipeline by UCB SA, H2 2017

Systemic Lupus Erythematosus - Pipeline by Xencor Inc, H2 2017

Systemic Lupus Erythematosus - Pipeline by XTL Biopharmaceuticals Ltd, H2 2017

Systemic Lupus Erythematosus - Pipeline by Zai Lab Ltd, H2 2017

Systemic Lupus Erythematosus - Dormant Projects, H2 2017

Systemic Lupus Erythematosus - Discontinued Products, H2 2017

List of Figures

Number of Products under Development for Systemic Lupus Erythematosus, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Ablynx NV
  • ACEA Biosciences Inc
  • AiCuris GmbH & Co KG
  • Amgen Inc
  • Asahi Kasei Pharma Corp
  • Atlantic Bio Sci LLC
  • Aurinia Pharmaceuticals Inc
  • Bio-Path Holdings Inc
  • Biogen Inc
  • Biotest AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Corestem Inc
  • CuraVac Inc
  • Deltanoid Pharmaceuticals Inc
  • Domainex Ltd
  • Eisai Co Ltd
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • Galapagos NV
  • Genentech Inc
  • Genosco Inc
  • Genovax Srl
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • HanAll Biopharma Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Idorsia Ltd
  • Immungenetics AG
  • Immunomedics Inc
  • Immunwork Inc
  • Immupharma Plc
  • Invion Ltd
  • Janus Biotherapeutics Inc
  • Johnson & Johnson
  • K-Stemcell Co Ltd
  • Karyopharm Therapeutics Inc
  • KPI Therapeutics Inc
  • Kyowa Hakko Kirin Co Ltd
  • Lead Discovery Center GmbH
  • LSK BioPartners Inc
  • MacroGenics Inc
  • MedAnnex Ltd
  • Medestea Research & Production SpA
  • MedImmune LLC
  • Merck & Co Inc
  • Merck KGaA
  • Millennium Pharmaceuticals Inc
  • Mitsubishi Tanabe Pharma Corp
  • Mount Tam Biotechnologies Inc
  • Nektar Therapeutics
  • Neovacs SA
  • Nippon Chemiphar Co Ltd
  • Novartis AG
  • Nuevolution AB
  • Omeros Corp
  • Pfizer Inc
  • Principia Biopharma Inc
  • Ra Pharmaceuticals Inc
  • RedHill Biopharma Ltd
  • Sarepta Therapeutics Inc
  • SBI Biotech Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • TheraMAB LLC
  • TxCell SA
  • UCB SA
  • Xencor Inc
  • XTL Biopharmaceuticals Ltd
  • Zai Lab Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll